Trial Profile
Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Hypertension; Metabolic syndrome
- Focus Therapeutic Use
- 24 Nov 2016 New trial record
- 01 Nov 2016 Results assessing effect of Valsartan on retinal capillary rarefaction in hypertensive patients (n=150) using patients data from this and other two trials (NCT01318395 and NCT00152698) published in the Journal of Clinical Hypertension (Greenwich)